Article
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive…
medRxiv · 2023 · Florencia P. Madorsky Rowdo
Key facts
| Title | Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment |
|---|---|
| First author | Florencia P. Madorsky Rowdo |
| Journal | medRxiv |
| Published | Jun 22, 2023 |
| DOI | 10.1101/2023.06.22.544406 |
| Devices mentioned | BK110039, DEN000008, K022086, K103302 |
| Product codes mentioned | JCI, KIT, NDS, NJT, OOI, PQP, PCA |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1